Cystic Fibrosis Pipeline Analysis Report 2026

Cystic fibrosis is a rare, inherited, life-threatening disorder caused by mutations in the CFTR gene, leading to the production of thick mucus that damages the lungs, pancreas, and other organs. Epidemiological evidence reported by Hassan Karami et al. (2025) indicates that the condition occurs in roughly 1 out of every 1000 newborns globally, with prevalence differing across regions. According to the cystic fibrosis pipeline analysis, the pipeline is expanding rapidly, driven by CFTR modulators, gene therapy, and personalized therapy approaches in this rare disease space. Increasing drug development, early diagnosis, clinical trials, and focus on disease-modifying therapies such as targeted therapy and precision medicine are expected to support sustained growth in the coming years, particularly under the orphan drug framework.

Report Coverage

The Cystic Fibrosis Pipeline Analysis Report gives comprehensive insights into cystic fibrosis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for cystic fibrosis. The cystic fibrosis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The cystic fibrosis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with cystic fibrosis treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to cystic fibrosis.

Cystic Fibrosis Pipeline Outlook

Cystic fibrosis is a rare, inherited genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator gene. It occurs when defective protein function disrupts salt and water transport, leading to thick mucus accumulation or mucus clearance that damages the lungs, pancreas, and other vital organs over time.

Cystic fibrosis treatment focuses on managing symptoms and correcting the underlying protein defect through CFTR modulators, inhalation therapy, airway clearance therapies, antibiotics, pancreatic enzyme replacement, and supportive nutritional care to improve lung function and survival. In December 2024, Vertex Pharmaceuticals announced United States Food and Drug Administration approval of ALYFTREK, a once-daily next-generation cystic fibrosis transmembrane conductance regulator modulator, expanding treatment eligibility and improving sweat chloride reduction compared to existing therapies in the pipeline.

Cystic Fibrosis Epidemiology

The pipeline analysis reflects steady advancement supported by well-defined disease incidence and expanding diagnosed populations. According to Hassan Karami et al. (2025), global cystic fibrosis prevalence ranges from approximately 1 in 3,000 to 1 in 6,000 live births, varying across regions. As per Vertex Pharmaceuticals, nearly 109,000 people are living with cystic fibrosis worldwide, with about 94,000 diagnosed across the United States, Europe, Australia, and Canada. The epidemiological burden supports increasing adoption of orphan drug development strategies and accelerated clinical trials, with strong emphasis on CFTR Modulators, gene therapy, and next-generation targeted therapy approaches for rare mutations. Overall, these developments indicate sustained innovation in drug development and long-term growth potential in the cystic fibrosis therapeutics landscape.

Cystic Fibrosis - Pipeline Therapeutic Assessment

This section of the report covers the analysis of cystic fibrosis drug candidates based on several segmentations, including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The cystic fibrosis pipeline analysis report covers 50+ drug analyses based on drug classes:

• Small Molecules
• Monoclonal Antibodies
• Peptides

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration:

• Oral
• Parenteral
• Others

Cystic Fibrosis Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 38%, covers a major share of the total cystic fibrosis clinical trials, driven by strong efficacy validation and dose-optimization efforts. Phase I follows at 25%, supported by active safety and tolerability studies. Phase III contributes 16%, while phase IV accounts for 12%. This distribution highlights continuous innovation, collectively supporting sustained growth.

Cystic Fibrosis Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the cystic fibrosis pipeline analysis include small molecules, monoclonal antibodies, and peptides. The cystic fibrosis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for cystic fibrosis. Messenger ribonucleic acid-based therapies represent an emerging drug class in the cystic fibrosis pipeline, targeting patients unresponsive to conventional modulators. For instance, ReCode Therapeutics’ RCT2100, an inhaled cystic fibrosis transmembrane conductance regulator messenger ribonucleic acid therapy, is under Phase II evaluation in combination with the CFTR modulator ivacaftor to improve lung function and disease outcomes.

Cystic Fibrosis Clinical Trials - Key Players

The report for the cystic fibrosis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed cystic fibrosis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in cystic fibrosis clinical trials:

• Vertex Pharmaceuticals Incorporated
• Krystal Biotech, Inc.
• Boehringer Ingelheim
• ReCode Therapeutics
• Spirovant Sciences, Inc.
• Cystetic Medicines, Inc.
• DevPro Biopharma
• 4D Molecular Therapeutics
• Sionna Therapeutics Inc.
• S-INFINITY Pharmaceuticals Co., Ltd.
• Arcturus Therapeutics, Inc.
• Respirion Pharmaceuticals Pty Ltd.

Cystic Fibrosis - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for cystic fibrosis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of cystic fibrosis drug candidates.

Drug: VX-121/TEZ/D-IVA

VX-121/Tezacaftor/Deutivacaftor is being developed by Vertex Pharmaceuticals Incorporated as an oral, once-daily triple-combination CFTR modulator for cystic fibrosis. The Phase 3 study is recruiting children aged 1-11 years and is examining pharmacokinetics, safety, tolerability, and efficacy in patients with at least one triple-combination-responsive CFTR mutation. VX-121 and tezacaftor are correctors that improve CFTR protein processing and trafficking to the cell surface, while deutivacaftor acts as a potentiator, enhancing channel opening to restore chloride transport, improve airway hydration, and support mucus clearance.

Drug: VX-522

VX-522 is an investigational inhaled mRNA therapy being developed and sponsored by Vertex Pharmaceuticals Incorporated for people with cystic fibrosis who are not responding to CFTR modulator therapies. The Phase 1/2 study is evaluating safety, tolerability, and preliminary efficacy while examining dose escalation outcomes. VX-522 is delivering full-length CFTR mRNA encapsulated in lipid nanoparticles directly to the lungs via inhalation. The therapy is enabling airway cells to produce functional CFTR protein, potentially restoring chloride transport and improving lung function in adults with non-responsive CFTR genotypes.

Drug: KB407

KB407 is a re-dosable inhaled gene therapy being developed by Krystal Biotech, Inc. for the treatment of cystic fibrosis. The ongoing Phase 1 study (NCT05504837) is evaluating the safety and tolerability of ascending doses in adults with cystic fibrosis. KB407 is using a replication-defective, non-integrating vector to deliver two copies of the full-length CFTR transgene directly to the lungs via nebulization. The therapy is enabling expression of functional, wild-type CFTR protein, aiming to restore ion transport, improve mucus clearance, and enhance lung function across CF genotypes.

Key Questions Answered in the Cystic Fibrosis Pipeline Insight Report

• Which companies/institutions are leading the cystic fibrosis drug development?
• Which company is leading the cystic fibrosis pipeline development activities?
• What is the current cystic fibrosis commercial assessment?
• What are the opportunities and challenges present in the cystic fibrosis pipeline landscape?
• What is the efficacy and safety profile of cystic fibrosis pipeline drugs?
• Which company is conducting major trials for cystic fibrosis drugs?
• Which companies/institutions are involved in cystic fibrosis collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in cystic fibrosis?

Reasons To Buy This Report

The Cystic Fibrosis Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for cystic fibrosis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into cystic fibrosis collaborations, regulatory environments, and potential growth opportunities.